Frontiers in Clinical Drug Research: Anti-Cancer Agents, Volume 6

Cover
Title
Copyright
End User License Agreement
Contents
Preface
List of Contributors
Immunomodulating Agents in the Treatment of Acute Myeloid Leukemia: A Combinatorial Immunotherapeutic Approach
Shazia Ali1, Dil Afroze1,*, Javid Rasool2, Bilal Rah4 and Khurshid I. Andrabi3
INTRODUCTION
Chemotherapeutic Drugs Used in the Treatment of AML
AML Relapse
PI3K/mTOR Pathway
mTOR Pathway in AML
TORC1 Targeted Therapy in mTOR
Novel Therapies in the Treatment of AML
FLT3 Mutation in AML as a Therapeutic Target
Targeting Isocitrate Dehydrogenase [IDH] Mutations in AML
Immunologic Approaches for the Treatment of AML
The Use of Inhibitors in the Treatment of AML and Concluding Remarks
FUNDING
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Potential Natural Products For Prostate Cancer Management: Prospects For Castration-Resistant Patients
Thaise G. Araújo1,*, Lara Vecchi1, Danilo S. Costa2, Sara T. S. Mota1, Paula M. A. P. Lima1, Igor M. Campos2, Mariana A. P. Zóia1, Douglas C. Brandão1, Gabriela S. Guimarães1, Matheus A. Ribeiro1 and Ademar A. da Silva Filho2
INTRODUCTION
OVERVIEW OF PROSTATE CANCER
Epidemiology and Etiopathology
Diagnosis Strategies and Current Treatments
Biomarkers
Prostate-Specific Antigen (PSA)
Pro-PSA
BPH-related PSA (BPSA)
Prostate Cancer Antigen 3 (PCA3)
TMPRSS2: ERG Fusion
Urokinase-Type Plasminogen Activator (Upa) and its Receptor (Upar)
Prostate-Specific Membrane Antigen (PSMA)
ANDROGEN RECEPTOR: FROM CURABLE TO LETHAL DISEASE
Hallmarks of CRPC
Signaling Pathways Involved in CRPC
TGF-β
Tyrosine Kinase Receptors
Il-6 Signaling
Wnt/frizzled/β-Catenin
NFkB
Approved Treatments for CRPC
CHALLENGES AND THE WAY FORWARD TO TREAT CRPC: NATURAL PRODUCTS AS ANTICANCER AGENTS
Terpenes
Betulinic Acid
Glycyrrhetinic Acid
Ursolic Acid
Ganoderic Acids
Lupeol
Oridonin
Artemisinin
Lycopene
Physachenolide D
Flavonoids
Luteolin
Apigenin
Quercetin
Genistein and other Soy Isoflavones
Silibinin
Baicalin and Baicalein
Alkaloids And Anthraquinones
Sanguinarine
Emodin
Other Phenolic And Miscellaneous Compounds
Resveratrol
Honokiol
Curcumin
Capsaicin and Derivatives
Wedelolactone
(-)-Epigallocatechin- 3-Gallate and other Polyphenols Form Green Tea
Gossypol
Phenethyl-Isothiocyanate
Ellagic Acid
Thymoquinone
Atraric Acid
Diindolylmethane
Sulforaphane
CONCLUDING REMARKS
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Inhibition of Key Protein-Protein Interactions by Small Molecules for Cancer Drug Design
Aykut Özgür1, Lütfi Tutar2, Mehmet Gümüş3, İrfan Koca4,*, Servet Tunoğlu5, Ezgi Nurdan Yenilmez Tunoğlu5 and Yusuf Tutar6,7,*
INTRODUCTION
P53-MDM2 INTERACTION
Small-Molecule Inhibitors of the p53–MDM2 Interaction
C-MYC-MAX INTERACTION
Small-Molecule Inhibitors of the c-Myc-Max Interaction
BCL-2/BCL-XL INTERACTION
Small-Molecule Inhibitors of Bcl-2/Bcl-xL Interaction
HSP90/HSP70 INTERACTION
Small-Molecule Inhibitors of the Hsp70/Hsp90 Interaction
Β-CATENIN/TCF4 INTERACTION
Small-Molecule Inhibitors of the β-Catenin/TCF4 Interaction
MENIN/MLL INTERACTION
Small-Molecule Inhibitors of the Menin-MLL Interaction
CONCLUSION
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) for Advanced Hepatocellular Carcinoma
Kei Moriya*, Tadashi Namisaki and Hitoshi Yoshiji
INTRODUCTION
The Best Choice for Managing Advanced Hepatocellular Carcinoma
What is Hepatic Arterial Infusion Chemotherapy (HAIC)?
One-shot HAIC and its Clinical Outcome for HCC
Reservoir Systems for Chemotherapy
Setting of Reservoir Systems
Management of Reservoir System and its Related Adverse Events
Reservoir HAIC Regimen and Clinical Outcome for HCC
Evaluation of the Curative Effect of HAIC and its Prognostic Value
Which Type of HAIC Would be Useful?
When to use HAIC Combination Therapy with Molecularly Targeted Drugs or Surgical Resection for Advanced HCC with Major Ductal Invasions
A New Derivation of Modified HAIC
Which is Better, HAIC, or Molecularly Targeted Agents?
SUMMARY
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Targeting Cancer Stem Cells: Implications in Health and Disease
Roshia Ali1,2,*, Hilal Ahmad Mir2, Rabia Hamid3, Sahar Saleem Bhat4 and Firdous A. Khanday2
INTRODUCTION
STEM CELLS
CANCER STEM CELLS
CSC NICHE - CROSS TALK BETWEEN CSC AND TUMOR MICROENVIRONMENT
CSC BIOMARKERS
CD133
CD24
CD44
ALDH
CSCS IN TUMORIGENIC PROCESS
THERAPEUTIC APPROACHES TO TARGET CSCS - PRECLINICAL AND CLINICAL ROUTE
Targeting Cellular Surface CSC Markers
Immunotherapeutic Approaches to Targeting CSCs
Targeting CSC Metabolism
Targeting Key Signal Pathways
CONCLUSION AND PERSPECTIVES
AUTHOR CONTRIBUTIONS
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Subject Index
Back Cover